



## Cell Cycle Proteins as Promising Targets in Cancer Therapy

Guest Editor:

**Prof. Arun K. Rishi**

Department of Oncology, School  
of Medicine, Wayne State  
University, Detroit, MI 48201, USA

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editor

Dear Colleagues,

The cell cycles in eukaryotic cells are dynamically regulated by extrinsic, growth factor-induced, mitogenic, and intrinsic signals from proteins that are involved in monitoring genomic integrity.

Many human cancers harbor amplified genes encoding Cyclin D1, CDK4/6, and/or Cyclin E1, which function as drivers of oncogenesis. As many CDKs are frequently and aberrantly activated in human cancers, a rationale for targeting CDKs for cancer therapy has emerged that has culminated into the current clinical use of pharmacological inhibitors of CDK4/6 kinases, while a number of pharmacological inhibitors of CDKs, CHK1, PLK, and aurora kinases are being tested in clinical trials.

With this Special Issue, we kindly invite our colleagues to submit their latest research findings or reviews covering new knowledge of the mechanisms and pathways involved in the regulation/control of cell cycles, as well as new knowledge of the regulation of mediators/transducers of cell cycles in cancer cells in in vitro and in vivo models. Papers describing novel inhibitors that target cell cycle transducers in basic and/or clinical settings are also welcomed.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)